A deep dive into Eli Lilly’s provocative Alzheimer’s drug data

What is it?

STAT + is the premium entry service of STAT for in-depth coverage and analysis of biotechnology, pharmaceutical, policy and life science coverage. Our award-winning team covers news about Wall Street, policy developments in Washington, early scientific breakthroughs and results of clinical trials, and disruption of health care in Silicon Valley and beyond.

What is included?

• Daily reporting and analysis
• The most comprehensive operational coverage of a powerhouse of reporters
• Subscriber newsletters only
• Daily newsletters to inform you of the most important industry news of the day
• STAT + talks
• Weekly opportunities to engage with our reporters and leading industry experts
• Exclusive business opportunities
• Premium access to online events for just subscribers across the country
• The best reporters in the industry
• The most trusted and well-connected newsroom in the healthcare industry
• And much more
• Exclusive interviews with industry leaders, profiles and premium tools, such as our CRISPR Trackr.